Literature DB >> 25877930

Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites.

Caroline Turcotte1, François Chouinard1, Julie S Lefebvre1, Nicolas Flamand2.   

Abstract

2-Arachidonoyl-glycerol (2-AG) and arachidonyl-ethanolamide (AEA) are endocannabinoids that have been implicated in many physiologic disorders, including obesity, metabolic syndromes, hepatic diseases, pain, neurologic disorders, and inflammation. Their immunomodulatory effects are numerous and are not always mediated by cannabinoid receptors, reflecting the presence of an arachidonic acid (AA) molecule in their structure, the latter being the precursor of numerous bioactive lipids that are pro- or anti-inflammatory. 2-AG and AEA can thus serve as a source of AA but can also be metabolized by most eicosanoid biosynthetic enzymes, yielding additional lipids. In this regard, enhancing endocannabinoid levels by using endocannabinoid hydrolysis inhibitors is likely to augment the levels of these lipids that could regulate inflammatory cell functions. This review summarizes the metabolic pathways involved in the biosynthesis and metabolism of AEA and 2-AG, as well as the biologic effects of the 2-AG and AEA lipidomes in the regulation of inflammation. © Society for Leukocyte Biology.

Entities:  

Keywords:  MAG lipase; anandamide; eicosanoid; leukocyte; leukotriene; prostaglandin

Mesh:

Substances:

Year:  2015        PMID: 25877930     DOI: 10.1189/jlb.3RU0115-021R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  78 in total

1.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

2.  Differential hepatoprotective role of the cannabinoid CB1 and CB2 receptors in paracetamol-induced liver injury.

Authors:  Patricia Rivera; Antonio Vargas; Antoni Pastor; Anna Boronat; Antonio Jesús López-Gambero; Laura Sánchez-Marín; Dina Medina-Vera; Antonia Serrano; Francisco Javier Pavón; Rafael de la Torre; Ekaitz Agirregoitia; María Isabel Lucena; Fernando Rodríguez de Fonseca; Juan Decara; Juan Suárez
Journal:  Br J Pharmacol       Date:  2020-04-15       Impact factor: 8.739

Review 3.  Polarity scaffolds signaling in epithelial cell permeability.

Authors:  Lauren F O'Leary; Andrea M Tomko; Denis J Dupré
Journal:  Inflamm Res       Date:  2021-03-15       Impact factor: 4.575

Review 4.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

5.  Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.

Authors:  Emma Leishman; Ben Cornett; Karl Spork; Alex Straiker; Ken Mackie; Heather B Bradshaw
Journal:  Pharmacol Res       Date:  2016-04-22       Impact factor: 7.658

Review 6.  Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.

Authors:  Gernot F Grabner; Robert Zimmermann; Rudolf Schicho; Ulrike Taschler
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

7.  Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?

Authors:  Timna Naftali
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

8.  Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors.

Authors:  Rosaria I Staiano; Stefania Loffredo; Francesco Borriello; Fabio Arturo Iannotti; Fabiana Piscitelli; Pierangelo Orlando; Agnese Secondo; Francescopaolo Granata; Maria Teresa Lepore; Alfonso Fiorelli; Gilda Varricchi; Mario Santini; Massimo Triggiani; Vincenzo Di Marzo; Gianni Marone
Journal:  J Leukoc Biol       Date:  2015-10-14       Impact factor: 4.962

Review 9.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

10.  Protective Action of Anandamide and Its COX-2 Metabolite against l-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes.

Authors:  Guangbi Li; Min Xia; Justine M Abais; Krishna Boini; Pin-Lan Li; Joseph K Ritter
Journal:  J Pharmacol Exp Ther       Date:  2016-05-11       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.